{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_lpsrsosytfazyl7bwslq","seq":1420843,"kind":"article","title":"FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC","url":"https://www.onclive.com/view/fda-grants-fast-track-designation-to-tre-515-plus-kras-inhibitors-in-pretreated-kras-g12c-nsclc","published":"2026-10-02T15:15:00Z","seen":"2026-10-02T19:59:11Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["education","economy","health"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q7886634","name":"Kras","type":"other"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_lpsrsosytfazyl7bwslq","category":"health","category_p":0.39,"category2":"science-technology","sentiment":"positive","tone":-0.1,"political":0.11},{"id":"n_gtunptrdmeflwhaulj4q","seq":1420836,"kind":"article","title":"NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC","url":"https://www.onclive.com/view/nda-submission-is-initiated-for-zipalertinib-plus-chemotherapy-in-frontline-egfr-exon-20-insertion-nsclc","published":"2026-10-02T14:29:00Z","seen":"2026-10-02T19:59:11Z","lang":"en","source":{"id":"onclive.com","name":"onclive.com","domain":"onclive.com","outlet":{"wikidata":"Q140944690","name":"OncLive","type":"website","designations":["publication","website"]}},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q131418163","name":"Zipalertinib","type":"other"},{"id":"Q14865565","name":"EGFR","type":"other"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_xqfzrdgyct27zowffaia","category":"health","category_p":0.58,"sentiment":"neutral","tone":-0.22,"political":0.27},{"id":"n_mee6zfe2qytmjgagc7ta","seq":647786,"kind":"press_release","title":"BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis","url":"https://www.globenewswire.com/news-release/2026/09/29/3370683/0/en/beyondspring-announces-fda-fast-track-designation-for-plinabulin-in-post-ici-non-squamous-nsclc-and-strategic-transaction-to-advance-global-phase-3-dublin-4-trial-toward-planned-in.html","summary":"FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing innovative therapies for the treatment of cancer and other diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to Plinabulin and docetaxel for the treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”) without…","published":"2026-09-29T11:01:00Z","seen":"2026-09-29T11:07:24Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:bysi","kyg108301006"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q15269699","name":"plinabulin","type":"other"},{"id":"Q899151","name":"Imperial Chemical Industries","type":"other"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"mentions":2,"story":"st_mee6zfe2qytmjgagc7ta","category":"health","category_p":0.33,"category2":"science-technology","sentiment":"neutral","tone":0.19,"political":0.06},{"id":"n_eu4nntpuwrkm5tuo47aa","seq":502059,"kind":"article","title":"Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC","url":"https://www.rdrnews.com/online_features/press_releases/innovent-announces-expansion-of-global-phase-3-marslight-11-study-of-ibi363-tak-928-alpha/article_c4caf8c3-39c5-567d-b0c9-9621f98696ee.html","summary":"SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic…","published":"2026-09-28T00:00:00Z","seen":"2026-09-28T19:01:26Z","lang":"en","country":"US","source":{"id":"kite-rdrnews-com-059ec0","name":"rdrnews.com","domain":"rdrnews.com","outlet":{"wikidata":"Q7370099","name":"Roswell Daily Record","type":"newspaper","country":"US","designations":["newspaper"]}},"via":"kite-rdrnews-com-059ec0","topics":["new-mexico"],"authors":["By Innovent Biologics"],"entities":[{"id":"Q30296199","name":"Innovent","type":"org"},{"id":"Q3658562","name":"non-small-cell lung carcinoma","type":"other"}],"story":"st_eu4nntpuwrkm5tuo47aa","category":"science-technology","category_p":0.69,"category2":"health","sentiment":"neutral","tone":0.17,"political":0.04}]}